AR106053A1 - Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer - Google Patents
Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncerInfo
- Publication number
- AR106053A1 AR106053A1 ARP160102832A ARP160102832A AR106053A1 AR 106053 A1 AR106053 A1 AR 106053A1 AR P160102832 A ARP160102832 A AR P160102832A AR P160102832 A ARP160102832 A AR P160102832A AR 106053 A1 AR106053 A1 AR 106053A1
- Authority
- AR
- Argentina
- Prior art keywords
- ona
- quinolin
- cancer treatment
- hydrogen
- imidazo compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000001257 hydrogen Substances 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 2
- 229910052731 fluorine Chemical group 0.000 abstract 2
- 239000011737 fluorine Chemical group 0.000 abstract 2
- 125000002393 azetidinyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicación 1: Un compuesto de fórmula (1), o una sal farmacéuticamente aceptable del mismo, caracterizado porque: R¹ es metilo; R² es hidrógeno o metilo; o R¹ y R² junto con el átomo de nitrógeno al cual están unidos forman un anillo azetidinilo, pirrolidinilo o piperidinilo; R³ es hidrógeno o flúor; R⁴ es hidrógeno o metilo; y R⁵ es hidrógeno o flúor.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1516504.6A GB201516504D0 (en) | 2015-09-17 | 2015-09-17 | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
AR106053A1 true AR106053A1 (es) | 2017-12-06 |
Family
ID=54544418
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160102832A AR106053A1 (es) | 2015-09-17 | 2016-09-16 | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer |
Country Status (37)
Country | Link |
---|---|
US (5) | US9856255B2 (es) |
EP (2) | EP3683220B1 (es) |
JP (1) | JP6605130B2 (es) |
KR (2) | KR102469153B1 (es) |
CN (1) | CN108137576B (es) |
AR (1) | AR106053A1 (es) |
AU (1) | AU2016323399B2 (es) |
BR (1) | BR112018004325B1 (es) |
CA (1) | CA2997399C (es) |
CL (1) | CL2018000677A1 (es) |
CO (1) | CO2018002829A2 (es) |
CR (1) | CR20180172A (es) |
CY (1) | CY1124680T1 (es) |
DK (2) | DK3683220T3 (es) |
DO (1) | DOP2018000065A (es) |
EA (1) | EA033284B1 (es) |
ES (2) | ES2853924T3 (es) |
GB (1) | GB201516504D0 (es) |
HK (2) | HK1255408A1 (es) |
HR (1) | HRP20210149T1 (es) |
HU (2) | HUE058884T2 (es) |
IL (1) | IL257847B (es) |
LT (1) | LT3350180T (es) |
MX (1) | MX2018003186A (es) |
MY (1) | MY195669A (es) |
NI (1) | NI201800033A (es) |
PE (1) | PE20181078A1 (es) |
PH (1) | PH12018500532A1 (es) |
PL (2) | PL3350180T3 (es) |
PT (2) | PT3350180T (es) |
RS (1) | RS61435B1 (es) |
SI (1) | SI3350180T1 (es) |
SV (1) | SV2018005655A (es) |
TN (1) | TN2018000078A1 (es) |
TW (2) | TWI762109B (es) |
WO (1) | WO2017046216A1 (es) |
ZA (1) | ZA202209171B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201516504D0 (en) * | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
GB201608227D0 (en) * | 2016-05-11 | 2016-06-22 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
JOP20190209A1 (ar) * | 2017-03-16 | 2019-09-12 | Astrazeneca Ab | مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان |
WO2019057757A1 (en) | 2017-09-20 | 2019-03-28 | Astrazeneca Ab | 1,3-DIHYDROIMIDAZO [4,5-C] CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER |
KR20210061337A (ko) * | 2018-09-14 | 2021-05-27 | 수저우 잔롱 파마 리미티드 | 모세혈관확장성 운동실조증 돌연변이(ATM) 키나제의 선택적 조절제로서의 1-이소프로필-3-메틸-8-(피리딘-3-일)-1,3-디하이드로-2H-이미다조[4,5-c]신놀린-2-온 및 이의 용도 |
CN115003672A (zh) * | 2020-01-09 | 2022-09-02 | 南京明德新药研发有限公司 | 喹啉并咪唑类化合物及其应用 |
US20230293507A1 (en) * | 2020-03-04 | 2023-09-21 | Pharos Ibio Co., Ltd | Use of 2,3,5-substituted thiophene compound for preventing, ameliorating, or treating ovarian cancer |
WO2021260580A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and atm inhibitor |
JP2023542419A (ja) * | 2020-09-28 | 2023-10-06 | 石薬集団中奇制薬技術(石家庄)有限公司 | 縮合環化合物及びその製造と使用 |
EP3992191A1 (en) | 2020-11-03 | 2022-05-04 | Deutsches Krebsforschungszentrum | Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors |
WO2022125614A1 (en) * | 2020-12-09 | 2022-06-16 | Stingray Therapeutics, Inc. | Phosphonates as inhibitors of enpp1 and cdnp |
AU2021433713A1 (en) * | 2021-03-17 | 2023-09-28 | Suzhou Zanrong Pharma Limited | Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof |
CN115304598B (zh) * | 2021-08-25 | 2024-05-31 | 石药集团中奇制药技术(石家庄)有限公司 | 一种杂环类化合物及其制备方法和用途 |
GB202114704D0 (en) | 2021-10-14 | 2021-12-01 | Univ Birmingham | ATM inhibition |
AU2023212227A1 (en) * | 2022-01-26 | 2024-08-15 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hydrazino group-containing compound |
AU2022452885A1 (en) * | 2022-04-11 | 2024-09-05 | Wei Zhong | Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one derivative crystal form, salt crystal form, preparation method and application |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ240313A (en) | 1990-10-22 | 1994-04-27 | Res Corp Technologies Inc | Anti-retrovirus compositions containing aryl and heteroaryl derivatives |
TW301607B (es) | 1993-03-09 | 1997-04-01 | Takeda Pharm Industry Co Ltd | |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
DK0880508T3 (da) | 1996-02-13 | 2003-06-30 | Astrazeneca Ab | Quinazolinderivater som VEGF-inhibitorer |
ATE211134T1 (de) | 1996-03-05 | 2002-01-15 | 4-anilinochinazolin derivate | |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
US6632823B1 (en) | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
JP2002522388A (ja) | 1998-08-03 | 2002-07-23 | ビーエーエスエフ コーポレーション | 性機能障害の治療のためのピリジノン |
CA2362401A1 (en) | 1999-02-04 | 2000-08-10 | Paul Fleming | G-protein coupled heptahelical receptor binding compounds and methods of use thereof |
US20020151712A1 (en) | 1999-09-14 | 2002-10-17 | Nan-Horng Lin | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission |
WO2002030357A2 (en) | 2000-10-11 | 2002-04-18 | Chemocentryx, Inc. | Compounds and methods for modulating ccr4 function |
AU2002213467A8 (en) | 2000-10-11 | 2009-07-30 | Chemocentryx Inc | Modulation of ccr4 function |
EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
WO2002076177A2 (en) | 2001-03-23 | 2002-10-03 | Bethesda Pharmaceuticals, Inc. | Design and synthesis of optimized ligands for ppar |
JP2002293745A (ja) | 2001-03-29 | 2002-10-09 | St Marianna Univ School Of Medicine | 慢性関節リウマチ治療剤 |
WO2003084997A1 (en) | 2001-04-10 | 2003-10-16 | Transtech Pharma, Inc. | Probes, systems and methods for drug discovery |
WO2002087618A1 (fr) | 2001-04-27 | 2002-11-07 | Takeda Chemical Industries, Ltd. | Methode de prevention et de traitement du cancer |
US7144903B2 (en) | 2001-05-23 | 2006-12-05 | Amgen Inc. | CCR4 antagonists |
EP1270535A3 (de) | 2001-06-20 | 2004-02-18 | Clariant GmbH | Verfahren zur Herstellung von substituierten aromatischen Verbindungen |
JP4082888B2 (ja) | 2001-10-17 | 2008-04-30 | 広栄化学工業株式会社 | ビアリール化合物の製造法 |
CA2473740A1 (en) | 2002-01-18 | 2003-07-31 | David Solow-Cordero | Methods of treating conditions associated with an edg receptor |
JP4167848B2 (ja) | 2002-04-10 | 2008-10-22 | 広栄化学工業株式会社 | ビアリール化合物の製造法 |
GB0211649D0 (en) | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
WO2004007472A1 (ja) | 2002-07-10 | 2004-01-22 | Ono Pharmaceutical Co., Ltd. | Ccr4アンタゴニストおよびその医薬用途 |
CA2496097A1 (en) | 2002-08-23 | 2004-03-04 | University Of Connecticut | Keto cannabinoids with therapeutic indications |
US20040087590A1 (en) | 2002-08-23 | 2004-05-06 | University Of Connecticut | Novel biphenyl and biphenyl-like cannabinoids |
WO2004078756A2 (en) * | 2003-03-06 | 2004-09-16 | Eisai Co., Ltd. | Jnk inhibitors |
EP1604971A4 (en) | 2003-03-11 | 2006-08-16 | Ono Pharmaceutical Co | PROCESS FOR ADDING ACTIVE CHARCOAL IN WATER PURIFICATION AND WATER PURIFICATION METHOD |
WO2004113258A1 (ja) | 2003-06-20 | 2004-12-29 | Shionogi & Co., Ltd. | 炭素−炭素結合生成反応 |
US7732442B2 (en) | 2003-09-05 | 2010-06-08 | Ono Pharmaceutical Co., Ltd. | Chemokine receptor antagonist and medical use thereof |
JP2005170939A (ja) | 2003-11-20 | 2005-06-30 | Takeda Chem Ind Ltd | 糖尿病の予防・治療剤 |
DE602004014969D1 (de) | 2003-11-21 | 2008-08-21 | Novartis Ag | 1h-imidazochinolinderivate als proteinkinaseinhibitoren |
WO2006038594A1 (ja) | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | N型カルシウムチャネル阻害薬 |
PL1826197T3 (pl) | 2004-12-13 | 2012-06-29 | Ono Pharmaceutical Co | Pochodna kwasu aminokarboksylowego i jej zastosowanie lecznicze |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
US20070032522A1 (en) | 2005-07-01 | 2007-02-08 | Kumar Dange V | Antiviral agents |
US20090306035A1 (en) | 2005-08-26 | 2009-12-10 | Emory University | Compounds and Methods for modulating the Silencing of a Polynucleotide of Interest |
JO3598B1 (ar) | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
JP2009023986A (ja) | 2006-11-08 | 2009-02-05 | Pharma Ip | 抗癌剤としてのビアリール誘導体 |
CL2008000191A1 (es) | 2007-01-25 | 2008-08-22 | Astrazeneca Ab | Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer. |
BRPI0807893A2 (pt) | 2007-02-20 | 2014-06-17 | Novartis Ag | Imidazoquinolinas como inibidores duais de lipídio quinase e mtor. |
MX2009009541A (es) | 2007-03-07 | 2009-09-16 | Alantos Pharm Holding | Inhibidores de metaloproteasa que contienen una porcion heterociclica. |
US8039505B2 (en) | 2007-04-11 | 2011-10-18 | University Of Utah Research Foundation | Compounds for modulating T-cells |
PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
US7928111B2 (en) | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
US9321730B2 (en) | 2007-08-21 | 2016-04-26 | The Hong Kong Polytechnic University | Method of making and administering quinoline derivatives as anti-cancer agents |
US20110020338A1 (en) | 2008-03-26 | 2011-01-27 | Carlos Garcia-Echeverria | 5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes |
US8841462B2 (en) | 2008-07-01 | 2014-09-23 | Robert A. Heald | Bicyclic heterocycles as MEK kinase inhibitors |
TW201028381A (en) | 2008-07-14 | 2010-08-01 | Shionogi & Co | Pyridine derivative having ttk inhibition activity |
WO2010038165A1 (en) | 2008-09-30 | 2010-04-08 | Pfizer Inc. | Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions |
NZ593937A (en) | 2008-12-08 | 2014-05-30 | Vm Pharma Llc | Compositions of protein receptor tyrosine kinase inhibitors |
US20120093917A1 (en) | 2009-04-02 | 2012-04-19 | Robert Hromas | Metnase and intnase inhibitors and their use in treating cancer |
TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
JP2012528829A (ja) * | 2009-06-04 | 2012-11-15 | ノバルティス アーゲー | 1H−イミダゾ[4,5−c]キノリノン化合物 |
BRPI1010621A2 (pt) * | 2009-06-04 | 2016-06-21 | Novartis Ag | derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso |
KR20140034948A (ko) | 2009-09-28 | 2014-03-20 | 에프. 호프만-라 로슈 아게 | 벤즈옥세핀 pi3k 억제제 화합물 및 사용 방법 |
GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
CN102199152A (zh) | 2010-03-25 | 2011-09-28 | 高大新 | 杂环咪唑类磷脂激酶抑制剂 |
CN102372711B (zh) * | 2010-08-18 | 2014-09-17 | 山东轩竹医药科技有限公司 | 咪唑并喹啉类PI3K和mTOR双重抑制剂 |
WO2012025213A2 (en) | 2010-08-23 | 2012-03-01 | Grünenthal GmbH | Novel therapeutic compounds |
DE102010035744A1 (de) | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
CN102399218A (zh) * | 2010-09-16 | 2012-04-04 | 和记黄埔医药(上海)有限公司 | 一类并合三杂环及其作为pi3k抑制剂的用途 |
AR083267A1 (es) | 2010-10-04 | 2013-02-13 | Novartis Ag | Combinaciones farmaceuticas |
PE20140792A1 (es) | 2010-12-03 | 2014-07-09 | Novartis Ag | Composiciones farmaceuticas |
CA2819955A1 (en) | 2010-12-06 | 2012-06-14 | Piramal Enterprises Limited | Substituted imidazoquinoline derivatives |
CN102603628B (zh) | 2010-12-22 | 2016-08-17 | 香港理工大学 | 作为抗癌试剂的喹啉衍生物 |
WO2012092471A2 (en) | 2010-12-29 | 2012-07-05 | Development Center For Biotechnology | Novel tubulin inhibitors and methods of using the same |
JO3003B1 (ar) * | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
WO2012138789A2 (en) | 2011-04-04 | 2012-10-11 | Netherlands Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment |
RU2017140639A (ru) | 2011-05-23 | 2019-02-12 | Элан Фармасьютикалз, Инк. | Ингибиторы активности киназы lrrk2 |
CA2837312A1 (en) | 2011-05-26 | 2012-11-29 | Sunovion Pharmaceuticals Inc. | Metabotropic glutamate receptor 5 allosteric modulators and methods of use thereof |
WO2013022740A2 (en) | 2011-08-05 | 2013-02-14 | Corning Incorporated | Gpr35 ligands and the uses thereof |
JP6042060B2 (ja) | 2011-09-26 | 2016-12-14 | サノフイ | ピラゾロキノリノン誘導体、その調製および治療上の使用 |
US9580409B2 (en) | 2011-11-07 | 2017-02-28 | Sunovion Pharmaceuticals, Inc. | Modulators of opioid receptors and methods of use thereof |
WO2013074965A1 (en) | 2011-11-16 | 2013-05-23 | Microbiotix, Inc. | Aminoalkyl phenol ether inhibitors of influenza a virus |
WO2013157018A1 (en) | 2012-04-18 | 2013-10-24 | Indian Institute Of Technology Madras | A process for the preparation of the core structure in quinolone and napthyridone class of antibiotics |
EP2858631A1 (en) | 2012-06-06 | 2015-04-15 | Novartis AG | Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease |
AU2013271731A1 (en) | 2012-06-07 | 2014-12-18 | Georgia State University Research Foundation, Inc. | SecA inhibitors and methods of making and using thereof |
WO2013192367A1 (en) | 2012-06-22 | 2013-12-27 | Novartis Ag | Neuroendocrine tumor treatment |
EP2885003B1 (en) | 2012-08-16 | 2021-09-29 | Novartis AG | Combination of pi3k inhibitor and c-met inhibitor |
WO2014031872A2 (en) | 2012-08-23 | 2014-02-27 | The Broad Institute, Inc. | Small molecule inhibitors for treating parasitic infections |
AU2014248568B2 (en) | 2013-03-12 | 2017-07-13 | Curegenix, Inc. | Compounds for treatment of cancer |
GB201309180D0 (en) | 2013-05-21 | 2013-07-03 | Ucl Business Plc | Compounds and Their Uses |
US20160264570A1 (en) | 2013-11-15 | 2016-09-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Method of blocking transmission of malarial parasite |
WO2015084384A1 (en) * | 2013-12-06 | 2015-06-11 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
NO2714752T3 (es) * | 2014-05-08 | 2018-04-21 | ||
GB201409044D0 (en) | 2014-05-21 | 2014-07-02 | Ucl Business Plc | New compounds |
ES2880626T3 (es) | 2015-04-02 | 2021-11-25 | Merck Patent Gmbh | Imidazolonilquinolinas |
CN104876912B (zh) | 2015-04-08 | 2017-07-21 | 苏州云轩医药科技有限公司 | Wnt信号通路抑制剂及其应用 |
EP3319938B1 (en) | 2015-07-10 | 2022-04-06 | University of Maryland, Baltimore | Small molecule inhibitors of the mcl-1 oncoprotein and uses thereof |
GB201516504D0 (en) * | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
JP6919977B2 (ja) | 2016-03-16 | 2021-08-18 | クラ オンコロジー,インク. | メニン−mllの置換された阻害剤及びその使用方法 |
-
2015
- 2015-09-17 GB GBGB1516504.6A patent/GB201516504D0/en not_active Ceased
-
2016
- 2016-09-14 TW TW109145998A patent/TWI762109B/zh active
- 2016-09-14 TW TW105129931A patent/TWI714631B/zh active
- 2016-09-15 RS RS20210170A patent/RS61435B1/sr unknown
- 2016-09-15 AU AU2016323399A patent/AU2016323399B2/en active Active
- 2016-09-15 PE PE2018000343A patent/PE20181078A1/es unknown
- 2016-09-15 ES ES16770461T patent/ES2853924T3/es active Active
- 2016-09-15 HU HUE20156172A patent/HUE058884T2/hu unknown
- 2016-09-15 TN TNP/2018/000078A patent/TN2018000078A1/en unknown
- 2016-09-15 DK DK20156172.7T patent/DK3683220T3/da active
- 2016-09-15 CN CN201680052951.0A patent/CN108137576B/zh active Active
- 2016-09-15 LT LTEP16770461.8T patent/LT3350180T/lt unknown
- 2016-09-15 MY MYPI2018701049A patent/MY195669A/en unknown
- 2016-09-15 PL PL16770461T patent/PL3350180T3/pl unknown
- 2016-09-15 PT PT167704618T patent/PT3350180T/pt unknown
- 2016-09-15 KR KR1020197028342A patent/KR102469153B1/ko active IP Right Grant
- 2016-09-15 KR KR1020187010323A patent/KR102028848B1/ko active IP Right Grant
- 2016-09-15 PT PT201561727T patent/PT3683220T/pt unknown
- 2016-09-15 CA CA2997399A patent/CA2997399C/en active Active
- 2016-09-15 WO PCT/EP2016/071782 patent/WO2017046216A1/en active Application Filing
- 2016-09-15 HU HUE16770461A patent/HUE053066T2/hu unknown
- 2016-09-15 SI SI201631074T patent/SI3350180T1/sl unknown
- 2016-09-15 ES ES20156172T patent/ES2920876T3/es active Active
- 2016-09-15 EA EA201890650A patent/EA033284B1/ru not_active IP Right Cessation
- 2016-09-15 DK DK16770461.8T patent/DK3350180T3/da active
- 2016-09-15 PL PL20156172.7T patent/PL3683220T3/pl unknown
- 2016-09-15 JP JP2018513812A patent/JP6605130B2/ja active Active
- 2016-09-15 CR CR20180172A patent/CR20180172A/es unknown
- 2016-09-15 EP EP20156172.7A patent/EP3683220B1/en active Active
- 2016-09-15 BR BR112018004325-7A patent/BR112018004325B1/pt active IP Right Grant
- 2016-09-15 EP EP16770461.8A patent/EP3350180B1/en active Active
- 2016-09-15 MX MX2018003186A patent/MX2018003186A/es unknown
- 2016-09-16 AR ARP160102832A patent/AR106053A1/es active IP Right Grant
- 2016-09-16 US US15/267,398 patent/US9856255B2/en active Active
-
2017
- 2017-11-27 US US15/822,617 patent/US10457679B2/en active Active
-
2018
- 2018-02-26 NI NI201800033A patent/NI201800033A/es unknown
- 2018-03-04 IL IL257847A patent/IL257847B/en active IP Right Grant
- 2018-03-06 DO DO2018000065A patent/DOP2018000065A/es unknown
- 2018-03-12 PH PH12018500532A patent/PH12018500532A1/en unknown
- 2018-03-14 CL CL2018000677A patent/CL2018000677A1/es unknown
- 2018-03-16 SV SV2018005655A patent/SV2018005655A/es unknown
- 2018-03-16 CO CONC2018/0002829A patent/CO2018002829A2/es unknown
- 2018-11-15 HK HK18114571.8A patent/HK1255408A1/zh unknown
- 2018-12-27 HK HK18116623.1A patent/HK1257413A1/zh unknown
-
2019
- 2019-09-27 US US16/584,996 patent/US10882858B2/en active Active
-
2020
- 2020-12-01 US US17/108,117 patent/US11613539B2/en active Active
-
2021
- 2021-01-29 HR HRP20210149TT patent/HRP20210149T1/hr unknown
- 2021-02-11 CY CY20211100117T patent/CY1124680T1/el unknown
-
2022
- 2022-08-16 ZA ZA2022/09171A patent/ZA202209171B/en unknown
-
2023
- 2023-02-21 US US18/171,735 patent/US20230286981A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR106053A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer | |
AR100340A1 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
AR119424A1 (es) | Derivados de 3-oxo-4h-quinoxalina y oxo-1h-naftiridina como inhibidores de parp | |
AR110400A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
AR098912A1 (es) | Inhibidores de syk | |
AR090220A1 (es) | Inhibidores de serina/treonina cinasa | |
AR100006A1 (es) | Derivados de tubulisina | |
AR102204A1 (es) | Compuestos derivados de amino-alquilbenzotiazepinas | |
PE20191245A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
EA030199B9 (ru) | Терапевтически активные соединения и способы их применения | |
PE20151939A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
AR092269A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
UY35641A (es) | PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO) | |
AR102977A1 (es) | Inhibidores de erk | |
AR094784A1 (es) | Compuestos de tubulisina, métodos para obtenerlos y uso | |
EA201690172A1 (ru) | Полиморф ингибиторов syk | |
AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
MA40171A (fr) | Dérivés d'azamophinan et leur utilisation | |
CY1119619T1 (el) | Παραγωγα πυριδιν-4-υλιου | |
AR094553A1 (es) | Formas de oxadiazolpirazina | |
AR097866A1 (es) | Derivados de 4-azaindol | |
CL2019001694A1 (es) | Compuestos de pirazolopirimidina y métodos de uso de los mismos. | |
AR096153A1 (es) | Derivados de pirrolo[2,3-d]pirimidina | |
EA201591456A1 (ru) | Макроциклические и бициклические ингибиторы вируса гепатита с | |
AR095015A1 (es) | Compuestos de azetidiniloxifenilpirrolidina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |